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Giant cell tumours (GCTs) of the small bones of the hands and feet are rare. Small case 
series have been published but there is no consensus about ideal treatment. We performed 
a systematic review, initially screening 775 titles, and included 12 papers comprising 
91 patients with GCT of the small bones of the hands and feet. The rate of recurrence across 
these publications was found to be 72% (18 of 25) in those treated with isolated curettage, 
13% (2 of 15) in those treated with curettage plus adjuvants, 15% (6 of 41) in those treated 
by resection and 10% (1 of 10) in those treated by amputation.
We then retrospectively analysed 30 patients treated for GCT of the small bones of the 
hands and feet between 1987 and 2010 in five specialised centres. The primary treatment was 
curettage in six, curettage with adjuvants (phenol or liquid nitrogen with or without 
polymethylmethacrylate (PMMA)) in 18 and resection in six. We evaluated the rate of 
complications and recurrence as well as the factors that influenced their functional outcome.
At a mean follow-up of 7.9 years (2 to 26) the rate of recurrence was 50% (n = 3) in those 
patients treated with isolated curettage, 22% (n = 4) in those treated with curettage plus 
adjuvants and 17% (n = 1) in those treated with resection (p = 0.404). The only complication 
was pain in one patient, which resolved after surgical removal of remnants of PMMA. We 
could not identify any individual factors associated with a higher rate of complications or 
recurrence. The mean post-operative Musculoskeletal Tumor Society scores were slightly 
higher after intra-lesional treatment including isolated curettage and curettage plus 
adjuvants (29 (20 to 30)) compared with resection (25 (15 to 30)) (p = 0.091). Repeated 
curettage with adjuvants eventually resulted in the cure for all patients and is therefore a 
reasonable treatment for both primary and recurrent GCT of the small bones of the hands 
and feet.
Cite this article: Bone Joint J 2013;95-B:838–45.
Giant cell tumour (GCT) is a relatively
common benign lytic lesion that accounts for
4% to 5% of primary bone tumours and
almost 20% of benign bone tumours.1 It
occurs mainly between the ages of 30 and
50 years and is slightly more common in
women.2,3 The most common sites are the
meta-epiphyseal regions of the long bones
(85%), with more than 50% located in the dis-
tal femur, proximal tibia and distal radius.4
GCT of the axial skeleton accounts for a fur-
ther 10%.2,4 It is rare in the small bones of the
hands and feet (between 1.7% and 5% of all
GCTs).5-11 The differential diagnosis includes
enchondroma, fibrous dysplasia, aneurysmal
bone cyst, osteomyelitis and brown tumour
from hyperparathyroidism.
The standard treatment of lesions in the long
bones is curettage, often with local adjuvants
such as phenol, liquid nitrogen (cryosurgery)
and/or polymethylmethacrylate (PMMA) to
reduce the recurrence rate, which has been
reported from 12% to 34%.12-16 More aggres-
sive lesions of the long bones with soft-tissue
extension, pathological fracture or involvement
of joints may be treated by en bloc resection.14,16
Only a few studies of GCT of the small
bones have been published. As most are single
case reports there is no consensus about the
preferred treatment, which ranges from curet-
tage (with or without adjuvants) to en bloc
resection and even amputation. Local recur-
rence rates anywhere between 0% and 100%
have been reported after surgical treatment.6-8,17
Most recurrences occur within two years of
surgery, and en bloc resection has been shown
to result in a lower rate of recurrence (0% to
50%).6-8,18,19 However, reconstruction after
resection may be difficult in cases of multi-
centric GCT of the small bones, which has
been reported in 7% to 18% of cases.5,20
Curettage without adjuvants may not afford
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complete tumour removal, resulting in a higher rate of
recurrence (0% to 100%).6,8,17,21,22 Radiation-induced sar-
coma has been reported in 5% to 10% of patients receiving
radiotherapy as adjuvant treatment, and it is therefore not
recommended for primary lesions.4,8
The aims of this multicentre study were first to perform
a systematic literature review of the surgical treatment of
GCT of the small bones. Secondly, we aimed to evaluate the
rates of complication and recurrence and attempt to define
any association between patient and tumour characteristics
and functional outcome after different surgical approaches.
Patients and Methods
We performed a systematic search of the literature on GCT
of the small bones published between 1 January 1990 and
17 January 2011. Search terms and MeSH headings used
were ‘giant cell tumours’, ‘GCT’, ‘small bones’, ‘hand
bones’, ‘foot bones’, and all the individual small bones sep-
arately. We identified 775 unique titles in PubMed,
EMBASE, Web of Science and Academic Search Premier.
All titles and abstracts were screened by two reviewers
(VCO, LH). Inclusion criteria were case series only pub-
lished after 1990 in English, Dutch, Portuguese, French,
Italian or German; other languages were excluded. Further-
more, we excluded papers that focused purely on radio-
logical and/or histopathological assessment of GCT of the
small bones, reviews without new clinical cases, and papers
on GCT of the long bones, GCT of soft tissue (GCT-ST),
diffuse-type GCT (DT-GCT) and GCT of the tendon sheath
(GCT-TS). After review of the 775 titles, 42 abstracts were
screened, of which 23 full-text articles were assessed. Full
text assessment resulted in 11 further exclusions, leaving a
total of 12 papers for systematic review (Fig. 1).6-9,17-19,21-25
In addition we retrospectively reviewed 31 consecutive
patients with primary GCT of the small bones from a total
of 570 consecutive patients with GCT (5.4%) treated
between 1987 and 2010 in the authors’ five tertiary referral
centres for orthopaedic oncology. One patient with a malig-
nant GCT after local recurrence was excluded. The
30 remaining patients had a mean follow-up of 7.9 years (2
to 26; median 5.2). No patient was lost to follow-up. There
were 17 men and 13 women with a mean age of 29.6 years
Titles identified through 
database searching
(n = 775)
Screening
Included
Eligibility
Identification
Additional titles identified 
through other sources
(n = 0)
Removal of duplicates
(n = 8)
Titles screened
(n = 767)
Titles excluded
- Prior to 1991 (240)
- Case reports (237)
- Other diagnosis (197)*
- Radiology/pathology (31)
- Reconstruction (16)
- Other languages (2)†
Abstracts assessed 
for eligibility
(n = 42)
Abstracts excluded
- Other diagnosis (6)*
- Case reports (5)
- Radiology/pathology (5)
- No abstract available (2)
- Duplicate (1)
Full-text studies assessed
for eligibility
(n = 23)
Studies included in 
systematic review
(n = 12)
Full-text studies excluded
- Case series ≤ 2 (3)
- Recurrent GCT in small 
bones of the hand (2)
- Review without new
cases (2)
- Same patients reported 
previously (1)
- Treatment not specified 
for small bones (1)
- No full-text available (1)
- Radiation therapy (1)
Fig. 1
Flowchart of the systematic literature search (* including but not limited to: giant cell tumour (GCT) of the long bones
(mainly distal radius), GCT of the axial skeleton, multifocal GCT, malignant GCT, other bone and soft-tissue tumours
(e.g. diffuse-type GCT, GCT of tendon sheath, chondroblastoma, chondrosarcoma, osteosarcoma), GCT in animals,
etc; † excluded languages were Chinese and Turkish).
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(13 to 68) (Table I). As primary treatment, six patients
underwent curettage, 18 curettage plus adjuvants (nine
phenol, five liquid nitrogen, two phenol and PMMA, one
liquid nitrogen and PMMA and one PMMA), and six resec-
tion (five en bloc and one marginal) (Table II). Thorough
curettage was followed by three cycles of phenolisation and
neutralisation with ethanol, or by three cycles of liquid
nitrogen, and subsequently by filling the cavity with either
bone graft or PMMA. A high-speed burr was used in nine
patients treated with curettage and adjuvants (Table II). In
the Leiden University Medical Center, Leiden, the Nether-
lands (centre 1) and the Centro Hospitalar do Porto – Hos-
pital Santo Antonio, Porto, Portugal (centre 5),
musculoskeletal pathologists graded the GCT histo-
logically, but this did not influence the choice of surgical
treatment. As extension of the tumour can be evaluated
very accurately on MR imaging, the purely radiological
grading system of Campanacci et al1 was not used. In prac-
tice, every GCT is treated according to its tumour charac-
teristics, such as site, the presence of a pathological fracture
and/or soft-tissue extension, instead of according to a spe-
cific grading system.
Data including age, gender, tumour site, soft-tissue
extension, pathological fracture, surgical treatment, local
adjuvants, local recurrence, complications and further sur-
gical treatment were collected. All data were complete.
Functional outcome was assessed at final follow-up using
the Musculoskeletal Tumor Society (MSTS) scoring
system26 and was available for 22 patients (73%). The
remaining patients were discharged from follow-up (n = 1),
relocated (n = 5) or had died (n = 2), and therefore could
not be reached by telephone and/or post.
Statistical analysis. Recurrence-free survival was calculated
for the three different treatment groups using Kaplan-
Meier survival analysis with 95% confidence intervals (CI),
and differences between the groups were analysed using the
log rank test. Associations between different patient and
tumour characteristics and the resulting recurrence rates
were calculated using Pearson’s chi-squared test and
Fisher’s exact test. Unpaired t-tests were used to compare
MSTS scores between different treatment groups. The
results were analysed statistically with SPSS v20.0 (IBM
SPSS Statistics, Chicago, Illinois) and a p-value < 0.05 was
used to denote statistical significance.
Results
Literature search. Data including number of cases, tumour
localisation, treatment, reconstruction, local recurrences
and complications from the studies included in our system-
atic review are listed in Table III. Within the
12 included studies, a total of 25 patients were treated with
curettage alone,6,8,17,21,22 15 were treated with
curettage and adjuvants6,8,9,25 and 41 were treated with
resection.6-8,18,19,22-24 A further ten patients from the stud-
ies were treated with amputation.6-8,17,21,22,25 Results from
our systematic review showed that the highest mean rate of
recurrence occurred after curettage alone (72% (0% to
100%); n = 18) followed by resection (15% (0% to 50%);
n = 6) and curettage with adjuvants (13% (0% to 50%);
n = 2). The lowest recurrence rates were reported after
amputation (10% (0% to 100%); n = 1); however, this is
associated with marked functional and aesthetic impair-
ment and is only indicated rarely as a salvage procedure.
Retrospective multicentre analysis. In our 30 patients the
anatomical distribution of the 12 cases of GCT in the bones
of the hand was first, second and third metacarpal bones
(two each), fourth and fifth metacarpal bones (one each),
scaphoid (two), and middle and distal phalanges (one
each). The anatomical distribution of the 18 GCT in the
bones of the foot was: talus (five), calcaneus (three),
cuneiform (two), cuboid (one), first and fourth metatarsal
bones (two each), and second, third and fifth metatarsal
bones (one each). No patient had a multicentric GCT.
There was soft-tissue involvement in seven patients (four in
small bones of the hand and three in the foot) and a
pathological fracture in six (four in small bones of the foot
and two in the hand; two patients had both soft-tissue
extension and a pathological fracture): only one of these
underwent resection. None of the patients had any intra-
articular involvement and none had distant or pulmonary
metastases. Two patients died respectively five and ten
years after their index surgery, both from conditions unre-
lated to the GCT.
Overall, eight patients had a first local recurrence (three
in metatarsal bones, three in metacarpal bones, one in a
phalange and one in the talus), with a mean time to recur-
rence of 14 months (6 to 31) (Fig. 2). The rate of recurrence
was 50% (three of six) in patients treated with isolated
curettage, 22% (four of 18) after curettage in conjunction
with local adjuvants and 17% (one of six) after resection
Table I. Patient characteristics
Characteristic (n, %) n = 30
Gender
Male 17 (57)
Female 13 (43)
Site
Foot 18 (60)
Hand 12 (40)
Treatment
Curettage  6 (20)
Curettage with adjuvants 18 (60)
Wide or marginal resection  6 (20)
Tumour characteristics
Soft-tissue extension  7 (23)
Pathological fracture  6 (20)
Complications  1 (3)
Local recurrence
First recurrence  8 (27)
Second recurrence  2
Third recurrence  1
Fourth recurrence  1
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(Table II). The Kaplan-Meier five-year estimated recur-
rence-free survival was 50% (95% confidence interval (CI)
1.6 to 2.4) for curettage, 76% (95% CI 1.7 to 2.2) for
curettage with adjuvants and 80% (95% CI 1.6 to 2.3) for
resection (log rank test, p = 0.404) (Fig. 3). The five-year
estimated recurrence-free survival was 69% (95% CI 1.8 to
2.2) for all intra-lesional treatments and 80% (95% CI 1.6
to 2.3) for resection (log rank test, p = 0.661). Surgical
treatment of the first local recurrence consisted of repeated
curettage with adjuvants (three with phenol and four with
PMMA) and repeated resection (one). One patient, who
had a total of four local recurrences, is currently free of
disease at 26 years after repeated curettage procedures
with variations of phenol, bone grafting and
PMMA (Table II).
There was no statistical association between the use of
different local adjuvants and the respective recurrence rate
(p = 0.28; chi-squared test) or the number of recurrences
(p = 0.40; chi-squared test). The same held true for
recurrence rate and type of intervention (p = 0.12; chi-
squared test), pathological fracture (p = 0.62; Fisher’s exact
test) and soft-tissue extension (p = 0.31 Fisher’s exact test).
The only minor complication reported was pain caused
by remnants of PMMA in one patient that resolved
completely after surgical removal of the PMMA fragment.
No other complications were reported in this series.
The mean MSTS for functional outcome at final follow-up
was 25 (15 to 30) for the four patients who underwent resec-
tion and 29 (20 to 30) for the 18 treated by curettage with or
without adjuvants (p = 0.091; unpaired t-test) (Table II).
Discussion
GCTs of the small bones are believed to behave more aggres-
sively than GCT of the long bones27-29; high recurrence rates
have been described after different types of surgery.6,8,17,21
Local recurrence rates from this study were comparable
to those described in the literature: 50% vs 72% for curet-
tage, 22% vs 13% for curettage with adjuvants and 17% vs
Table II. Individual patient characteristics, treatments and outcomes
Treatment‡ Local recurrence
Patient/Gender/
Age (yrs) Centre* Site†
Soft-tissue 
extension
Pathological 
fracture Primary Reconstruction n
Time to
recurrence 
(mths) Treatment§ Complications
Follow-
up (mths)MSTS¶
Final 
outcome**
1 / F / 31 1 MT5 - Yes R (m) Non-vascularised fibular 
graft
1 9 R + bone graft - 78 30 NED
2 / M / 34 1 Cuneiform - - C + phenol + PMMA - 0 - - - 24 - NED
3 / M / 35 1 MC1 - - C Bone graft 1 8 C + PMMA Surgical removal 
(PMMA remnants 
causing pain)
88 - NED
4 / M / 20 1 MT1 Yes Yes (intra-
articular)
C + phenol Non-vascularised fibular 
graft + K-wires
2 6; 4 1) C + phenol + PMMA; 2)
C + PMMA + non-vascularised 
fibular graft
- 94 30 NED
5 / F / 23 1 MC2 - - C Bone graft 4 20; 57; 127; 3 1) C + PMMA; 2) C + bone graft; 
3) C + bone graft; 4) C + high-
speed burr + phenol + bone
graft
- 267 28 NED
6 / M / 40 1 MC2 Yes - C Bone graft + K-wires 0 - - - 46 - NED
7 / M / 60 1 MC3 - - C + phenol Bone graft 0 - - - 120 - DOOD
8 / F / 37 1 Talus Yes - C + phenol Bone graft 1 31 C + phenol + bone graft - 102 28 NED
9 / M / 20 1 MC3 Yes - C + PMMA - 1 7 C + PMMA - 117 30 NED
10 / F / 15 1 Talus - - C Bone graft 0 - - - 24 - NED
11 / F / 13 1 MT1 - - C + phenol + PMMA†† - 0 - - - 28 28 NED
12 / F / 22 1 MT3 - - C + phenol Bone graft 1 15 C + phenol + bone graft - 47 - NED
13 / F / 46 1 Ph3 - Yes C - 1 14 C + phenol + bone graft - 24 29 NED
14 / M / 20 2 Cuboid - - C + high-speed burr + 
phenol
Bone graft 0 - - - 63 30 NED
15 / M / 24 2 Calcaneus - - R (eb) Bone graft 0 - - - 68 15 NED
16 / F / 38 2 Scaphoid - - R (eb) Bone graft + screw fixa-
tion
0 - - - 122 28 NED
17 / F / 68 2 Calcaneus - - C + phenol Bone graft 0 - - - 128 30 NED
18 / F / 22 2 MT4 - - R (eb) Transposition of MT3 0 - - - 24 - NED
19 / F / 15 3 MT2 - - R (eb) Non-vascularised fibular 
graft
0 - - - 105 29 NED
20 / M / 25 3 Ph2 Yes - C Bone graft 0 - - - 118 30 NED
21 / M / 22 3 Talus Yes Yes (intra-
articular)
C + high-speed burr + 
phenol
Bone graft 0 - - - 67 30 NED
22 / M / 40 3 Talus - Yes C + high-speed burr + 
phenol
Bone graft 0 - - - 24 20 NED
23 / F / 22 4 MC1 - Yes (intra-
articular)
C + high-speed burr + 
liquid nitrogen
Bone graft 0 - - - 53 30 NED
24 / M / 15 4 Talus - - C + high-speed burr + 
liquid nitrogen
Bone graft 0 - - - 24 30 NED
25 / M / 45 4 MC4 - - C + high-speed burr + 
liquid nitrogen + PMMA
- 0 - - - 30 30 NED
26 / M / 15 4 Cuneiform - - C + high-speed burr + 
liquid nitrogen
Bone graft 0 - - - 61 30 NED
27 / M / 36 4 MC5 Yes - C + high-speed burr + 
liquid nitrogen
Bone graft 0 - - - 49 28 NED
28 / F / 17 4 MT4 - - C + high-speed burr +
liquid nitrogen
Bone graft 0 - - - 58 30 NED
29 / M / 51 5 Scaphoid - - R (eb) Bone graft + K-wires 0 - - - 61 - DOOD
30 / M / 18 5 Calcaneus - - C + phenol Bone graft 0 - - - 32 30 NED
* 1, Leiden University Medical Center (Leiden, the Netherlands); 2, Centro Traumatologico Ortopedico AOU-Careggi (Florence, Italy); 3, Nuffield Orthopaedic Centre (Oxford, United Kingdom); 4, Radboud University Medical Center 
(Nijmegen, the Netherlands); 5, Centro Hospitalar do Porto – Hospital Santo Antonio (Porto, Portugal) 
† MT, metatarsal; MC, metacarpal; Ph2/3, middle/distal phalanx 
‡ R (m/eb), resection (marginal/en bloc); C, curettage; PMMA, polymethylmethacrylate; K-wire, Kirschner wire 
§ including reconstruction 
¶ MSTS, Musculoskeletal Tumor Society score 
** NED, no evidence of disease; DOOD, died from other disease 
†† PMMA was replaced with a non-vascularised fibular graft five months after the index surgery, to allow for better function in the long term for this young patient
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15% for resection. The rate of recurrence of GCT of the
small bones in the literature and in our group were at the
higher end of the ranges reported in the literature for GCT
of the long bones, which are 27% to 65% after
curettage,1,12 12% to 34% after curettage with
adjuvants12,13,16 and 0% to 12% after resection.12,14 Risk
factors for recurrence such as soft tissue extension were not
more common (23%) than in those reported for long bones
Table III. Overview of the literature on surgical treatment of giant cell tumour (GCT) of the small bones
Local recurrence
Author/s
Patients/
Lesions 
(n)
Mean age (yrs) 
(range)
Mean follow-up 
(yrs) (range) Site* Primary treatment† Reconstruction‡ n (%)
Mean time to 
recurrence (mths) 
(range) Treatment§ Complications¶
Functional 
outcome**
Metastasis 
(n, %)
Picci et al22 52 (9)†† 31.1 (SD 14.7) 2 MC (4), P (2), Cb 
(1), MT (1), Cc (1)
Amputation (2); Mar-
ginal resection (6); 
Curettage (1)
0 - - NR NR NR
Sanjay et al19 7 (7) 24.6 (14 to 35) 10.9 (7 to 15) MC (6), P (1) Wide resection (7) Internal fixation with 
K-wires (4); Bone 
graft (3); Index finger 
transposition (1)
1‡‡ (14) 3 Resection NR NR 1 (14)
Athanasian et 
al8
14 (13)§§ 32.7 (11 to 54) 5.8 (1 to 39) MC (7), P (5), S (1) Wide resection (2) - 1 (50) 17 Pending (lung metastasis) 1 gross intrale-
sional contamina-
tion after resection
NR 2 (15)
Amputation (1) - 0 - -
Curettage (8) Bone graft (5) 7 (88) 6 (3 to 10) First (6): Curettage (3, 1 with phe-
nol); Resection (4, 1 with EBRT). 
Second (6): Curettage with phe-
nol (1); Resection (5, 1 with EBRT)
Curettage with burr (1) 
+ Curettage with phe-
nol (1)
Bone graft (2) 1 (50) 7 Resection
Biscaglia et al6 29 (26)¶¶ 27.4 (26 to 59) 6.75 (1 to 28) T (9), MC (8), Cb 
(3), Cn (3), MT (3), 
N (2), Cc (1)
Resection (6) - 1 (17) 5 Amputation NR NR 0
MC disarticulation (1) Arthrodesis (1) 0 - -
Curettage (11) Bone graft (14) 7 (64) 15 Resection (3); Curettage with 
phenol (2); Curettage (1); 
Amputation (1)
Curettage with phenol 
(8)
- 0 - -
Patradul et al23 3 (3) 23 (18 to 31) 3 MC (2), P (1) Resection (3) Bone graft and
osteosynthesis
(K-wires) (3)
1 (33) 12 Marginal resection NR Satisfac-
tory§§
NR
Wittig et al9 3 (3) 23.7 (16 to 33) 4.5 (4 to 5) P (2), MC (1) Curettage with liquid 
nitrogen and PMMA 
(3)
Osteosynthesis (K-
wires) (3)
0 - - 1 minor wound 
necrosis
ROM and 
grip 
strength 
within nor-
mal limits
0
Kamath et al25 8 (3)§§ 28.8 (13 to 47) 3 (3 to 15) Cc (1), T (1),
Cn (1)
2 curettage with burr 
and H2O2
Bone graft (2) 1 (50) 24 Curettage with PMMA NR NR NR
1 amputation - 0 - -
Ozalp et al21 5 (5) 41.6 (27 to 74) 7.8 (4 to 17) MC (2), P (3) 4 curettage Bone graft (2); 
Arthrodesis (1)
3 (75) 8 (2 to 18) First (3): Wide resection (1); Mar-
ginal resection (1); Ray 
amputation (1). Second (1): Ray 
amputation
NR NR 0
1 ray amputation - 1 (100) 6 First: Soft-tissue resection. 
Second: Advanced amputation***
Ropars et al17 4 (4) 40.5 (25 to 72) 3 (2 to 8) P (3), MC (1) 3 amputation - 0 - - NR NR NR
1 curettage Bone graft (1) 1 (100) 4 First: Resection. Second: 
Resection
Limited 
ROM
Minhas et al7 19 (7)§§ 24.3 (SD 5.7) 4.5 MC (4), P (3) 6 wide resection; 1 ray 
resection
Bone graft (6) 0 - - 0 NR NR
Vergara et al24 3 (3) 27 (18 to 38) NR P (1), Carpal 
bone††† (1), MC (1)
3 resection Bone graft (1); Bone 
elongation (2); MCP 
joint arthroplasty (1)
0 - - NR Limited 
ROM
NR
Ge et al18 8 (8) 28.5 3.8 MC (3), MT (4), P 
(1)
Wide resection (8) Bone graft and 
osteosynthesis (8)
2 (25) 12 (11 to 14) Wide resection (2) NR Excel-
lent§§§
0
Current study 30 (30) 29.6 (13 to 68) 7.9 (2 to 26) MC (8), MT (7), T 
(5), Cc (3), S (2), P 
(2), Cn (2), Cb (1)
Curettage (6) Bone graft (5) 3 (50) 14 (8 to 20) First (3): Curettage with phenol 
(1); Curettage with PMMA (2). 
Second (1): Curettage.Third (1): 
Curettage. Fourth (1): Curettage 
with phenol
Pain due to cement 
remnants after 
treatment of a 
recurrence (1)
MSTS: 
mean 29 
(20 to 30)
0
Curettage with adju-
vants (18: 9 phenol, 2 
phenol and PMMA, 1 
PMMA, 5 liquid nitro-
gen, 1 liquid nitrogen 
and PMMA)
Bone graft (13); Non-
vascularised fibula 
with K-wires (1)
4 (22) 15 (6 to 31) First (4): Curettage with phenol 
(2), Curettage with PMMA (2). 
Second (1): Curettage with 
PMMA
See above
Resection (6) Bone graft (3: 1 with 
K-wires); Non-vascu-
larised fibula (2); 
Transposition MT3 
(1)
1 (16) 9 Resection MSTS: 
mean 25 
(15 to 30)
* MC, metacarpal; P, phalanx; Cb, cuboid; MT, metatarsal; Cc, calcaneus; S, scaphoid; T, talus, Cn, cuneiform; N, navicular
† PMMA, polymethylmethacrylate; H2O2, hydrogen peroxide 
‡ K-wire, Kirschner wire; MCP, metacarpophalangeal; MT3, third metatarsal § EBRT, external beam radiation therapy 
¶ NR, not reported 
** ROM, range of movement; MSTS, Musculoskeletal Tumor Society score 
†† the other patients had non-GCT lesions of the small bones of the hands and feet. Two of the nine GCTs were referred with local recurrence
‡‡ soft-tissue recurrence only §§ the other patients had GCT in sites other than the small bones of the hands and feet 
¶¶ only 26 patients underwent surgical treatment; the remaining three were under observation 
*** forearm amputation because of soft-tissue extension ††† not further specified §§§ not specified which method was used to assess functional outcome
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(22% to 25%).15,30 Complete removal of GCT of the small
bones can be difficult for both intra-lesional and wide
resections, which may be explained by the technically chal-
lenging anatomical locations, the difficulty of applying ade-
quate local adjuvants due to anatomical restrictions, their
very rare incidence, which is likely to result in the surgeon’s
relative lack of experience. The differences between the
rates of recurrence with the various treatment options in
our study were not statistically significant and our sample
size was too small to detect differences after the use of var-
ious local adjuvants. The mean time to local recurrence in
our series was also consistent with the literature about GCT
of both long and small bones: only one patient had a first
recurrence more than two years after surgery (Tables II and
III). 
En bloc resection and ray amputation have been advo-
cated in technically challenging cases, as they are believed
to minimise the risk of recurrence.6,8,17,21,22,25,27 However,
similar recurrence rates have been reported for both resec-
tion (15%) and curettage with adjuvants (13%), indicating
that resection is not necessarily better.18,23 Wide resection
may also be associated with reduced function of the
affected hand or foot. Reconstruction of a defect is often
required such as bone grafting, osteosynthesis or joint
replacement, thereby increasing the duration of rehabilita-
tion and the risk of late complications.18,23,24,31
In this multicentre series the recurrence rate after curet-
tage with adjuvants (22%) was somewhat higher than the
mean rate of recurrence reported in the literature
(13%)6,8,9,25 for GCT of the small bones but remained
within the range reported after curettage with adjuvants for
GCT of the long bones (12% to 34%).12-16 Furthermore, in
our study all first recurrences except one were successfully
treated with repeated curettage and local adjuvants,
Fig. 2a
Imaging of a 22-year-old female patient (no. 12) with giant cell tumour of the third metatarsal bone of the right
foot. Figure 2a and 2b – radiographs a) pre-operatively, showing an expanding lytic lesion without cortical dis-
ruption in the metaphysis of the third metatarsal bone and b) at three months after primary curettage with phe-
nol and bone grafting. Figures 2c and 2d – radiograph (c) and T2-weighted MR scan (d) at one year post-
operatively, showing signs of local recurrence with secondary aneurysmal bone cysts. Figures 2e and 2f –
radiographs e) at three months after repeat curettage, phenol and bone grafting and f) at one year after treat-
ment for local recurrence, showing complete incorporation of the graft. At a final follow-up of four years there
are no signs of further recurrence or pulmonary metastasis.
Fig. 2b Fig. 2c
Fig. 2d Fig. 2e Fig. 2f
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thereby avoiding a more aggressive surgical approach.
Finally, all patients were free of disease. This suggests that
curettage with adjuvants can be a feasible treatment option
for both primary and recurrent GCT of the small bones.
Neither the type of local adjuvant or surgical treatment
nor the presence of a pathological fracture or soft-tissue
extension was associated with a higher risk of recurrence.
To our knowledge, such associations for GCT of the small
bones have not previously been studied. In the literature,
authors often referred to the potentially more aggressive
behaviour of GCT of the small bones, which reflect the
higher rates of multicentricity (7% to 18%)5,20 compared
with the rate of multicentricity in GCT of the long bones
(approximately 1%).28 Of all multicentric GCTs, up to
61% have been reported in the small bones of the hands
and feet.28,29 Interestingly, our study does not describe any
patient with multicentric GCT and are unable to corrobo-
rate previous reports.
Only a few studies reported post-operative complica-
tions, which included a reduced range of movement and
wound necrosis after curettage with adjuvants.8,9,31 We
encountered only one minor complication of pain after
curettage with PMMA due to cement remnants.
The role of different local adjuvants should be consid-
ered, considering the complications they may cause. Phenol
in high concentrations is toxic to soft tissues and some stud-
ies have questioned its efficacy,15,16 whereas others reported
no difference between phenol and other adjuvants.32,33 The
use of a high-speed burr allows the removal of tumour cells
from the walls of the tumour cavity but also destroys
healthy cancellous bone and carries the risk of dissemina-
tion of tumour.34 Cryosurgery may result in thermal injury
to surrounding healthy soft tissues, bone or cartilage.35
PMMA is used both as a local adjuvant and as filling mate-
rial, which is believed to substantially reduce the risk of
recurrence due to thermal necrosis and its direct toxic effect
on tumour cells but without producing major complica-
tions.36 However, it is not always necessary to fill the defect
in a small bone. Nevertheless, to reduce the risk of recur-
rence we recommend the use of local adjuvants after curet-
tage.
Few authors have described functional outcome after
surgery for GCT of the small bones.9,18,23,24 In two studies
it was described as satisfactory or excellent but the method
of assessment was not reported.18,23 Three other studies
reported a limited or normal range of movement after
resection or curettage for GCT of the bones of the
hand.9,17,24 In this study we assessed functional outcome
using the MSTS scoring system with the results being
slightly better after intra-lesional surgery than after resec-
tion.
Our study has several limitations. First, it was retrospec-
tive and even recruiting from several centres, to obtain a
larger group of patients, the sample size remained too small
to comment with confidence on differences in the rates of
recurrence after the use of various adjuvants. Second, the
multicentre design implies that multiple treatment strate-
gies have been applied, which may have resulted in selec-
tion and treatment bias.
In conclusion, we found the lowest rate of recurrence for
resection, followed by curettage with adjuvants. Curettage
alone was consistently associated with the highest rate of
recurrence. We were unable to identify any factors that were
associated with a higher risk of complication or recurrence.
From the literature en bloc resection and ray amputation are
associated with functional and aesthetic disability and are
rarely indicated as a salvage procedure. Repeated curettage
with adjuvants eventually resulted in the cure of all patients
in our series. Therefore, curettage with adjuvants is a feasible
treatment option for both primary and recurrent GCT of the
small bones of the hands and feet.
No benefits in any form have been received or will be received from a commer-
cial party related directly or indirectly to the subject of this article.
This article was primary edited by A. Ross and first-proof edited by G. Scott.
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